Related Experiment Video
Updated: May 12, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Clinical Model-Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric
Zachary L Taylor1,2,3, Takanobu Nadai1, Kei Irie1
1Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Clinical Pharmacology and Therapeutics
|May 11, 2026
Summary
Model-informed precision dosing (MIPD) tailors medication for children, moving beyond one-size-fits-all approaches. This personalized strategy optimizes drug effectiveness and safety by considering individual patient factors.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacy
Background:
- Traditional pediatric dosing often uses a "one-size-fits-all" approach, failing to account for significant patient variability.
- Pediatric patients exhibit unique physiological changes impacting drug response, making standardized dosing suboptimal.
- Existing pediatric dosing primarily considers age and size, which explain only a fraction of drug variability.
Purpose of the Study:
- To describe the implementation and operation of a Model-Informed Precision Dosing (MIPD) consultation service in a pediatric hospital.
- To illustrate the integration of precision dosing workflows into routine pediatric clinical care using real-world examples.
- To provide a practical framework for the broader adoption of MIPD in pediatric settings.
Main Methods:
- Utilized pharmacometrics to characterize drug behavior and identify patient-specific covariates influencing variability.
- Integrated quantitative pharmacological models with clinical data (drug concentrations, biomarkers) for MIPD.
- Established and operated an MIPD consultation service within an academic children's hospital.
Main Results:
- Demonstrated the feasibility of establishing and operating an MIPD consultation service in a pediatric academic center.
- Provided real-world examples showcasing the successful integration of precision dosing into clinical workflows.
- Identified key considerations and a practical blueprint for disseminating MIPD services.
Conclusions:
- MIPD offers a robust framework to overcome limitations of traditional dosing in pediatrics.
- Implementing an MIPD service can significantly advance personalized therapy and improve patient outcomes.
- Sharing operational experiences is crucial for bridging the gap towards widespread MIPD adoption in children's healthcare.
Related Concept Videos
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...